NextCure Inc. (NXTC) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 12 wire items for NXTC, including 7 SEC filings, 3 insider trades and 1 earnings update. The most recent was published Nov 13, 2026.
Financial highlights
Full financials- Net income, TTM
- -$40.97M
- Cash
- $8.73M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks42+300%
2026-05-172026-11-08
Mix1790d
- SEC Filings12(71%)
- Insider3(18%)
- Earnings1(6%)
- 13D/G1(6%)
Activity · 52 weeks7340 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by NextCure Inc.SCHEDULE 13G/A - NextCure, Inc. (0001661059) (Subject)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $62,897 worth of shares (12,333 units at $5.10) (SEC Form 4)4 - NextCure, Inc. (0001661059) (Issuer)
- SECSEC Form 10-Q filed by NextCure Inc.10-Q - NextCure, Inc. (0001661059) (Filer)
- SECNextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- PRNextCure Provides Business Update and Reports Third Quarter 2026 Financial ResultsAdvancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing S-4 Declared Effective by SEC; Stockholder Vote Scheduled for December 9, 2026 BALTIMORE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), today provided a business update and reported financial results for the third quarter ended September 30, 2026. The Company continues to advance its proposed merger (the "Merger") with Avere Therapeutics, Inc., a privately held biotechnology company focused on oral therapies for IL-23-driven inflammatory diseases ("Avere"), which is now supported by approximately $820 million of committed f
- INSIDERLarge owner Adar1 Capital Management, Llc bought $23,899 worth of shares (4,686 units at $5.10) (SEC Form 4)4 - NextCure, Inc. (0001661059) (Issuer)
- SECSEC Form EFFECT filed by NextCure Inc.EFFECT - NextCure, Inc. (0001661059) (Filer)
- SECSEC Form 424B3 filed by NextCure Inc.424B3 - NextCure, Inc. (0001661059) (Filer)
- SECAmendment: SEC Form S-4/A filed by NextCure Inc.S-4/A - NextCure, Inc. (0001661059) (Filer)
- SECAmendment: SEC Form S-4/A filed by NextCure Inc.S-4/A - NextCure, Inc. (0001661059) (Filer)
- SECNextCure Inc. filed SEC Form 8-K: Leadership Update8-K - NextCure, Inc. (0001661059) (Filer)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $53,691 worth of shares (10,851 units at $4.95) (SEC Form 4)4 - NextCure, Inc. (0001661059) (Issuer)
- SECAmendment: SEC Form S-4/A filed by NextCure Inc.S-4/A - NextCure, Inc. (0001661059) (Filer)
- SECSEC Form 425 filed by NextCure Inc.425 - NextCure, Inc. (0001661059) (Subject)
- SECNextCure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- SECNextCure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- SECSEC Form S-4 filed by NextCure Inc.S-4 - NextCure, Inc. (0001661059) (Filer)
- SECSEC Form SCHEDULE 13G filed by NextCure Inc.SCHEDULE 13G - NextCure, Inc. (0001661059) (Subject)
- INSIDERFormer 10% Owner Simcere Zaiming, Inc. sold $184,800 worth of shares (30,000 units at $6.16) (SEC Form 4)4 - NextCure, Inc. (0001661059) (Issuer)
- SECSEC Form 425 filed by NextCure Inc.425 - NextCure, Inc. (0001661059) (Subject)
- PRAvere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Avere Therapeutics, Inc. ("Avere" or the "Company"), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, today announced a $500 million private placement (the "Private Placement") from a syndicate of leading healthcare investors. The Private Placement is in addition to the previously announced $320 million concurre
- SECSEC Form 10-Q filed by NextCure Inc.10-Q - NextCure, Inc. (0001661059) (Filer)
- SECNextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- PRNextCure Provides Business Update and Reports Second Quarter 2026 Financial ResultsAnnounced Proposed Merger with Avere TherapeuticsPreserving Capital in Support of Merger Closing; Continuing Clinical Transition and Legacy Asset Activities BELTSVILLE, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today provided a business update and reported second quarter 2026 financial results. "Following quarter end, we announced our proposed merger with Avere Therapeutics, together with Avere’s concurrent private financing expected to generate approximately $320 million in gross proceeds, and we are working toward a closing in the second half of
- SECSEC Form 425 filed by NextCure Inc.425 - NextCure, Inc. (0001661059) (Subject)
NXTC FAQ
10 questionsWhat does NextCure Inc. do?
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a...What is the latest news on NXTC?
In the last 30 days Quantisnow tracked 12 wire items for NXTC: 7 SEC filings, 3 insider trades, 1 earnings update and 1 13D/G filing. The most recent was published on November 13, 2026.Is NXTC profitable?
No. NextCure Inc. reported a net loss of $40.97M for the twelve months ended Sep 30, 2026.How much cash and debt does NXTC have?
NextCure Inc. reported $8.73M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does NXTC stock trade?
NextCure Inc. (NXTC) is listed on NASDAQ.What sector and industry is NXTC in?
NextCure Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NextCure Inc. go public?
NextCure Inc. (NXTC) completed its IPO in 2019.What are analysts saying about NXTC?
Across the last 4 analyst actions on NextCure Inc., there were 1 upgrade and 1 downgrade. The most recent action was from Ladenburg Thalmann: Buy with a $18.00 price target on 2025-11-07. Recent price targets range from $14.00 to $18.00.What companies are similar to NXTC?
Notable peers in the same industry include CGEN (Compugen Ltd.), IMCR (Immunocore Holdings plc), AGEN (Agenus Inc.), IOVA (Iovance Biotherapeutics Inc.), RCUS (Arcus Biosciences Inc.). Compare NXTC side-by-side with any of them on Quantisnow.How can I track NXTC on Quantisnow?
Quantisnow aggregates NextCure Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NXTC to receive live email and push alerts on every new disclosure.